Sponsors of MS ActiveSource
MS ActiveSource is made possible by the support, resources and expertise of two leading biotechnology companies, Biogen Idec and Elan. Both are committed to advancing the treatment of multiple sclerosis. In addition to developing therapies for MS, Biogen Idec and Elan also created MS ActiveSource so people with MS could have a comprehensive resource for services and support.
About Biogen Idec
Biogen Idec Inc. (NASDAQ: BIIB), is a global biotechnology leader in neurology, oncology and immunology products. The company is committed to transforming scientific discovery into advances in healthcare. Biogen Idec pursues the creativity of science with passion and discipline. For more than 25 years, the company has grown through the discovery, development and commercialization of its own innovative products and through strategic alliances. Biogen Idec’s products are currently helping patients in more than 90 countries. One of the most well-known and widely used of these products, is AVONEX® (Interferon beta 1-a). AVONEX is indicated for the treatment of patients with relapsing forms of multiple sclerosis and is the most prescribed product in MS worldwide with close to 130,000 patients on therapy.
Biogen Idec is headquartered in Cambridge, MA, and was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc., founded in Switzerland in 1978, and IDEC Pharmaceuticals Corporation, founded in San Francisco, CA, in 1985.
The company maintains research centers of excellence in San Diego, CA and Cambridge. Biogen Idec has additional offices in Canada, Australia, Japan and throughout Europe, including international headquarters in Zug, Switzerland.
About Elan
Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. The company focuses on four areas of strength and is organized into the following business groups – Autoimmune diseases, Neurodegenerative diseases, Drug Technologies and Specialty Business.
Advances made by Elan’s Research and Development team based in South San Francisco have brought novel therapies to market, including TYSABRI (natalizumab), a new class of therapy for patients suffering from relapsing forms of multiple sclerosis, and PRIALT (ziconotide intrathecal infusion), a non-opioid analgesic, a synthetic equivalent of a conopeptide found in a marine snail known as Conus magus, administered intrathecally to patients suffering from severe chronic pain.
This tradition extends to Elan’s work in neurology and immunology for the treatment of Alzheimer’s, Parkinson’s, Multiple Sclerosis and Crohn’s Disease. The Drug Technologies business addresses drug optimization challenges through exclusive capabilities like NanoCrystal technology, which has the potential to improve the bioavailability, safety, administration and efficacy of drugs. The Specialty Business group focuses on the unique needs of medical Specialists operating in teaching-academic hospitals and specialty pain centers in the U.S.
Elan Corporation, plc is headquartered in Dublin, Ireland. The company’s shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.
